|
1
|
Schröpfer A, Kammerer U, Kapp M, Dietl J,
Feix S and Anacker J: Expression pattern of matrix
metalloproteinases in human gynecological cancer cell lines. BMC
Cancer. 13:5532010.PubMed/NCBI
|
|
2
|
Wu X, Li H, Kang L, Wang W and Shan B:
Activated matrix metalloproteinase-2: a potential marker of
prognosis for epithelial ovarian cancer. Gynecol Oncol. 84:126–134.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Planagumà J, Liljeström M, Alameda F, et
al: Matrix metalloproteinase-2 and matrix metalloproteinase-9
codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at
the invasive front of endometrial and ovarian carcinoma. Hum
Pathol. 42:57–67. 2011.PubMed/NCBI
|
|
4
|
Wang FQ, So J, Reierstad S and Fishman DA:
Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by
activation of progelatinase. Int J Cancer. 114:19–31. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moss NM, Barbolina MV, Liu Y, Sun L,
Munshi HG and Stack MS: Ovarian cancer cell detachment and
multicellular aggregate formation are regulated by membrane type 1
matrix metalloproteinase: a potential role in I.p. metastatic
dissemination. Cancer Res. 69:7121–7129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang LW, Garrett AP, Bell DA, Welch WR,
Berkowitz RS and Mok SC: Differential expression of matrix
metalloproteinase-9 and tissue inhibitor of metalloproteinase-1
protein and mRNA in epithelial ovarian tumors. Gynecol Oncol.
77:369–376. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim TJ, Rho SB, Choi YL, et al: High
expression of tissue inhibitor of metalloproteinase-2 in serous
ovarian carcinomas and the role of this expression in ovarian
tumorigenesis. Hum Pathol. 37:906–913. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davidson B, Goldberg I, Gotlieb WH, et al:
High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with
poor survival in ovarian carcinoma. Clin Exp Metastasis.
17:799–808. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Davidson B, Reich R, Berner A, et al:
Ovarian carcinoma cells in serous effusions show altered MMP-2 and
TIMP-2 mRNA levels. Eur J Cancer. 37:2040–2049. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davidson B, Goldberg I, Gotlieb WH,
Kopolovic J, Ben-Baruch G, Nesland JM and Reich R: The prognostic
value of metalloproteinases and angiogenic factors in ovarian
carcinoma. Mol Cell Endocrinol. 187:39–45. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kamat AA, Fletcher M, Gruman LM, et al:
The clinical relevance of stromal matrix metalloproteinase
expression in ovarian cancer. Clin Cancer Res. 12:1707–1714. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Périgny M, Bairati I, Harvey I, et al:
Role of immunohistochemical overexpression of matrix
metalloproteinases MMP-2 and MMP-11 in the prognosis of death by
ovarian cancer. Am J Clin Pathol. 129:226–231. 2008.PubMed/NCBI
|
|
13
|
Rauvala M, Puistola U and
Turpeenniemi-Hujanen T: Gelatinases and their tissue inhibitors in
ovarian tumors; TIMP-1 is a predictive as well as a prognostic
factor. Gynecol Oncol. 99:656–663. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sillanpää SM, Anttila MA, Voutilainen KA,
et al: Prognostic significance of matrix metalloproteinase-7 in
epithelial ovarian cancer and its relation to β-catenin. Int J
Cancer. 119:1792–1799. 2006.PubMed/NCBI
|
|
15
|
Sillanpää S, Anttila M, Suhonen K, et al:
Prognostic significance of extracellular matrix metalloproteinase
inducer and matrix metalloproteinase 2 in epithelial ovarian
cancer. Tumour Biol. 28:280–289. 2007.PubMed/NCBI
|
|
16
|
Sillanpää S, Anttila M, Voutilainen K, et
al: Prognostic significance of matrix metalloproteinase-9 (MMP-9)
in epithelial ovarian cancer. Gynecol Oncol. 104:296–303.
2007.PubMed/NCBI
|
|
17
|
Benedet JL, Bender H, Jones H III, Ngan
HYS and Pecorelli S: FIGO staging classifications and clinical
practice guidelines in the management of gynecologic cancers. FIGO
Committee on Gynecologic Oncology. Int J Gynecol Obstet.
70:209–262. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brun JL, Cortez A, Commo F, Uzan S,
Rouzier R and Daraï E: Serous and mucinous ovarian tumors express
different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Int J Oncol. 33:1239–1246. 2008.PubMed/NCBI
|
|
19
|
Skacel M, Skilton B, Pettay JD and Tubbs
RR: Tissue microarrays: a powerful tool for high-throughput
analysis of clinical specimen: a review of the method with
validation data. Appl Immunohistochem Mol Morphol. 10:1–6. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Graesslin O, Cortez A, Fauvet R, Lorenzato
M, Birembaut P and Darai E: Metalloproteinase-2, -7 and -9 and
tissue inhibitor of metalloproteinase-1 and -2 expressions in
normal, hyperplastic and neoplastic endometrium: a
clinical-pathological correlation study. Ann Oncol. 17:637–645.
2006. View Article : Google Scholar
|
|
21
|
Budwit-Novotny DA, McCarty KS, Cox EB, et
al: Immunohistochemical analyses of estrogen receptor in
endometrial adenocarcinoma using a monoclonal antibody. Cancer Res.
46:5419–5425. 1986.PubMed/NCBI
|
|
22
|
Bland JM and Altman DG: Multiple
significance tests: the Bonferroni method. BMJ. 310:1701995.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cai KQ, Yang WL, Capo-Chichi CD, et al:
Prominent expression of metalloproteinases in early stages of
ovarian tumorigenesis. Mol Carcinogen. 46:130–143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shigemasa K, Tanimoto H, Sakata K, et al:
Induction of matrix metalloprotease-7 is common in mucinous ovarian
tumors including early stage disease. Med Oncol. 17:52–58. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Afzal S, Lalani EN, Poulsom R, et al:
MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible
implications for the role of desmoplastic fibroblasts. Hum Pathol.
29:155–165. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sakata K, Shigemasa K, Nagai N and Ohama
K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP)
and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors
of the ovary. Int J Oncol. 17:673–681. 2000.PubMed/NCBI
|
|
27
|
Määttä M, Santala M, Soini Y,
Talvensaari-Mattila A and Turpeenniemi-Hujanen T: Matrix
metalloproteinases 2 and 9 and their tissue inhibitors in low
malignant potential ovarian tumors. Tumor Biol. 25:188–192.
2004.PubMed/NCBI
|
|
28
|
Behrens P, Rothe M, Florin A, Wellman A
and Wernert N: Invasive properties of serous human epithelial
ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression.
Int J Mol Med. 8:149–154. 2001.PubMed/NCBI
|
|
29
|
Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu
S, Oner U and Uray M: Prognostic value of matrix
metalloproteinase-9 (gelatinase B) expression in epithelial ovarian
tumors. Eur J Gynaecol Oncol. 24:417–420. 2003.PubMed/NCBI
|
|
30
|
Adley BP, Gleason KJ, Yang XJ and Stack
MS: Expression of membrane type 1 matrix metalloproteinase (MMP-14)
in epithelial ovarian cancer: high level expression in clear cell
carcinoma. Gynecol Oncol. 112:319–324. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Demeter A, Sziller I, Csapo Z, et al:
Molecular prognostic markers in recurrent and in non-recurrent
epithelial ovarian cancer. Anticancer Res. 25:2885–2889.
2005.PubMed/NCBI
|
|
32
|
Lengyel E, Schmalfeldt B, Konik E, et al:
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts
survival in advanced ovarian cancer. Gynecol Oncol. 82:291–298.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin YG, Han LY, Kamat AA, et al: EphA2
overexpression is associated with angiogenesis in ovarian cancer.
Cancer. 109:332–334. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin CK, Chao TK, Yu CP, Yu MH and Jin JS:
The expression of six biomarkers in the four most common ovarian
cancers: correlation with clinicopathological parameters. APMIS.
117:162–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
